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1. Introduction 
Mycobacterium tuberculosis is a causative agent of 
tuberculosis (TB) that has latently infected a third of the world 
population. Infection caused via inhalation of few droplets containing M. 
tuberculosis bacilli [1-3]. After infection, M. tuberculosis pathogenesis 
takes place in two stages.  
 An asymptomatic state that can persist for many years in the host, 
called latent TB.  
 The second stage requires only a weakened immune response to 
become activated (Zhang, 2004), then the bacteria begins replicating 
and causing typical symptoms such as cough, chest pain, fatigue and 
unexplained weight loss. If left untreated, the disease eventually 
culminates in death.  
The appearance of Human Immunodeficiency Virus (HIV) and 
the Acquired Immune Deficiency Syndrome (AIDS) epidemic emphasized 
the significance of reactivation of the disease. Over 50% of deaths among 
HIV infected patient results from co-infection with M. tuberculosis with 
the two pathogens inducing each other’s replication, thus accelerate the 
collapse of the immune system. The World Health Organization (WHO) 
report estimates that close to 2 million deaths occur every year, that 
there are around 8 million new cases per annum, and that every third 
person on the earth has been exposed to or infected by M. tuberculosis 
[4-7]. Even though TB can be treated and even cured with chemotherapy, 
treatment is lengthy and takes 6-9 months [8]. In addition to lengthy 
therapy, significant toxicity and poor patient compliance, drug resistant 
and multidrug resistant TB (MDR-TB) bacteria are seen [1-3]. Currently, 
TB chemotherapy is made up of first-line drugs, isoniazid (INH), 
Rifampicin (RIF), pyrazinamide (PZA) and ethambutol (EMB), which are 
given for six months. If this treatment fails due to bacterial drug 
resistance or intolerance to one or more drugs, second-line drugs are 
used (para-aminosalicilate (PAS), kanamycin, fluoroquinolones, 
capreomycin, ethionamide and cycloserine). These are generally less 
effective or more toxic with severe side effects [8-10]. This second-line 
treatment can also ineffective since MDR-strains that exhibit resistance 
to second-line drugs [11]. Treatment is also quite difficult by the 
presence of metabolically silent, persistent or dormant tubercular 
bacteria within host lesions. These are not susceptible to the anti-TB 
drugs that usually kill growing but not persistent bacteria [12]. There are 
so many reasons for drug resistance, including prescription of 
inadequate regimens, an uncertain drug supply, ineffective drugs, 
duration of lengthy treatments is one of the major contributors because 
some TB patients prematurely stop their therapy after an initial, rapid 
heath improvement, thereby favoring the appearance of drug-resistant 
strains [5,13]. 
1.1 Rational drug design 
In new pharmacophore groups, one problem that must be 
considered in the design of anti-TB compounds is that there is a 
subpopulation of bacteria in a persistent non-replicating state. This is 
considered a major contributing factor to long drug treatments for TB 
[14]. For this reason, it is important to determine if compounds have 
potential activity against these bacteria at the onset of design. The 
physicochemical properties were also studies that directly affect the 
pharmacokinetics and pharmacodynamics of drugs. This is the influence 
of stereoisomers on biological activity, because individual enantiomers 
have significant differences in activity, although sometimes the activity of 
some enantiomers cannot be explained. 
 
2. Non fluoroquinolones 
A quinoline ring is one of the moieties frequently used in drug 
design and development. It has been calculated a pharmacophore for the 
design of anti-TB agents (Fig 1). Diarilquinoline (TMC207) (1), is an 
adenosine ATP synthase inhibitor that is one of the most important non 
fluorinated quinoline compound with anti-TB activity. Butanamide is 
established as an important pharmacophore with good antibacterial 
activity and the carbohydrazone moiety is also known as a 
pharmacophore group. The design of new quinoline derivatives with 
active carbohydrazine and butanamide moieties in 3 and 4-position, 
respectively, has been carried out. These compounds shows that the 
presence of a trifluoromethyl group at 8-position increases activity; 
however, the fluoro group in 6-position partially decreases activity (2) 
and these type of compounds were nontoxic [15]. The development of 
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mefloquine analogs (3) in a series of compounds (4), good anti-TB 
activity has been recognized to the presence of biologically active 
heterocyclic groups like pyrazole, imidazole, and indole rings on the 
quinoline moiety. Compounds with a pyrazole ring have activity against 
resistant strains, which can be accredited to the presence of electron 
donating groups that stabilize the pyrazole ring, making the more active 
entity of quinoline ring [16].The conformational restriction of the 
piperidinyl ring of mefloquine through the construction of an oxazolidine 
ring and different substituents on the phenyl ring (5).Conformational 
restriction showed that the introduction of an oxazolidine core in the 
mefloquine moiety improved anti-TB activity. The activity of these 
compounds is affected by substituents on the aromatic ring bound to C-
17 of the oxazolidenyl nucleus. Compounds that show hydroxyl or 
methoxyl groups, which are both electron donators and capable of 
forming strong hydrogen bonds, are active. Compounds with nitro or 
halogenated groups (electron withdrawing groups and capable of 
forming only weak hydrogen bonds) are inactive [17]. The mefloquineis 
used to design anti-TB compounds, introduction of a hydrazone linker 
into mefloquine at 4-position, substitution of a piperidine with a 
piperazine ring and extension of the basic terminus of the piperazine 
ring at 4-position. Isoxazoleis rising as one of the most powerful hits in 
high-throughput screening against TB. Both types of compounds show an 
aromatic ring, a two-atom linker and a five or six member ring. 
Hybridization strategies have been the basis for the design of new 
chemical compounds (6). One problem that has been detected in these 
compounds is poor penetration of acid derivatives through the 
M.tuberculosis cell wall. These compounds may act as prodrugs when 
ester derivatives generate acid derivatives (6). These compounds show 
that when a methyl group replaces a trifluoromethyl group, it is 10 times 
less active, suggesting that electronic effects may play an important role 
in anti-TB activity. Steric effects can also affect anti-TB activity. 
Subsequently, ester bioisosteres (amides and oxadiazole), none of these 
bioisosteres showed better activity than ester derivatives. Compound 
that 2 and 8-trifluoromethyl groups on quinoline ring (6) are essential 
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6 
Figure 1: Quinoline as scaffold for designing new anti-TB agents  
(1-6). 
Isoxazole derivatives have been reported as anti-TB agents, 
compound 7 with an activity of 2.9 μM, which is comparable to INH and 
RIF[19]. Thus, quinoline and oxazole ring hybridization were used to 
develop a series of new anti-TB agents (8) which have good activity due 
to presence of aryl substituents at 2-position on quinoline ring. The 
introduction of a 1,3-oxazole ring significantly increases activity that is 
more potent than INH [15]. New moiety that confers anti-TB activity 
with low cytotoxicity, methoxybenzofuro[2,3-b]quinoline derivatives (9), 
that have a potent M. tuberculosis growth inhibition of 99% at low 
(0.20μg/ml) concentrations  and very low cytotoxicity with an inhibitor 
concentration 50 (IC50) value of > 30.00μg/ml[20].Several studies have 
investigated modifications in the quinolone ring, mainly at 3,6 and 7-
position. They made a modification in the 2-position, including an 
aliphatic side chain with various degrees of unsaturation, lengths chains, 
and double bond positions (10). The results showed that increasing the 
chain length enhances anti-TB activity, showing optimal activity with 14 
C atoms. There is an increase of more carbon atoms in the chain, activity 
decreases dramatically. This behavior has also been described for 
ciprofloxacin derivatives where lipophilicity could play an important role 
in anti-TB activity. The saturated aliphatic chain has less activity than 
unsaturated analogues. The unsaturation of an aliphatic chain is an 








Figure 2: Quinoline and oxazole derivatives as anti-TB agents  
(7-10). 
Phenazine and quinoxaline rings are considered bioisosteres 
of the quinoline ring. Phenazine derivatives are useful compounds for 
new anti-TB drug development, particularly Tubermicyn B and 
Clofazimine (phenazinean alouges). Similarly, new compounds that show 
activity (11) in a concentration range of 0.19 to 3.12 mg/l against 
tubercular resistant clinical isolates. This series of compounds were 
ineffective in inhibiting the growth of INH resistant strains. Compounds 
that had exocyclic groups, which present different lipophilic and 
electronic properties, but with a size similar to INH, such as phenylamide 
methyl lipophilic group in 4-position, were the most active. Same group 
in 3-position is reduced activity 100-fold. Phenazine derivatives having 
electron withdrawing groups in 2 and 3-position have similar biological 
activity. The importance of the arylic moiety is a pharmacophore for 
phenazinecarboxamide anti-TB compounds. Mechanism of action of 
phenazine derivatives is still unknown and hypothesized that it could act 
as a cellular superoxide bismutase inhibitor. The compound Lomofungin 
(1-carbomethoxy-5-formyl-4,6,8-trihydroxyphenazine) is capable of 
inhibiting DNA-dependent RNA polymerase, both these options may be 
possible for mechanisms of action of phenazine derivatives [22]. 
Quinoxalines compounds have broad spectrum of biological activities. 
Quinoxaline-N oxide derivatives are known as M. tuberculosis 
bioreductor agents. Compounds missing N-oxide groups have led to the 
loss of anti-TB activity. Over 500 derivatives of quinoxaline (12), 
demonstrating the importance of this group for developing a new class of 
anti-TB compounds. The quinoxaline compounds have activity on 
nonreplicating bacteria, which could lead to shorter anti-TB activity[23]. 
A compound denominated ER-2 is a new derivative of quinolines (13), is 
a gyrase supercoiling inhibitor and has potency similar to Ciprofloxacin 






Figure 3: Structure of phenazine-1-carboxamides, quinoline and 
quinoxaline derivatives (11-13). 
 
3. Hydrazides/hydrazones derivatives  
Hydrazide/hydrazone compounds (Fig 4) have been 
considered for new anti-TB drug design. An example is diflunisal, which 
has dual effect acting with antimicrobial and anti-inflammatory 
activities. In thiazolylhydrazone derivatives have found that 
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substitutions on the phenyl ring affect anti-TB activity (14) [25]. A 
thiazolylhydrazine is compound (15), which has high anti-TB activity 
with an IC50 of 6.22 μg/ml and low toxicity (CC50> 40 μg/ml), pyridyl 
moiety plays a direct role related to anti-TB activity [26]. A series of 
pyridine compounds have potential anti-TB activity (16)[27]. New 
designs have been made by molecular hybridization of E-cinamic acid 
and guanylhydrazones. The electronic and steric parameters have an 
important role in the activity of these compounds on M. tuberculosis 









Figure 4: Hydrazone derivatives as anti-TB agents (14-17). 
 
4. Nitrogen heterocyclic derivatives 
Purines (Fig 5) are an important group in the design of anti-
TB drugs. In these compounds (18), activity depends on the substituents 
present in C2, C6 and N9 of the purine ring [29]. In 6,9-disubtituted 
purine derivatives, activity increases substantially when a Cl atom is 
presented in the 2-position. Purine derivatives with thienyl substituents 
exhibited better activity in non-replicating bacteria, although in these 
compounds a Cl atom in 2-position is not beneficial for activity. The 
purine N-9 is important for activity, in the case of purine C-8, an atom 
can be exchanged without losing activity and a change in purine N-7 
results in a loss of activity, although there are 7-deazapurines derivatives 




Figure 5: Purine derivatives as anti-TB agents (18,19). 
 
Heterocycles, pyrimidines have potential therapeutic 
applications as anti-TB agents. The design of pyrimidine derivatives is a 
possible option (20, Figure 6). The substituent nature in 2-position can 
modulate cytotoxic activity [31]. The thymidine monophosphate kinase 
of M. tuberculosis (TMPKmt) is a prominent target for the development of 
anti-TB drugs. TMPK is the last specific enzyme for dTTP synthesis and is 
a key enzyme in M. tuberculosis metabolism. This enzyme is different 
from human enzyme analogs (22% homology). TMPK inhibitors have 
been developed with single or multiple chemical modifications of the 
pyrimidine moiety and thymidylate sugar. In particular benzyl-thymine 
derivatives have been remarkable TMPK inhibitors, which has led to the 
proposal of new modifications such as: chain length in para-position on 
the benzyl ring, saturation of the alkyl chain, functionalization of the 
chain group and substitution at 5-position of the core base. This has led 
to more selective compounds on TMKP that correspond to benzyl-
pyrimidines substituted by a chain length of 4 carbons and a terminal 
carboxylic acid function. Docking of molecule 21on TMPKmt showed that 





Figure 6: General structure of pyrimidine derivatives as anti-TB 
agents (20,21). 
Pyridine derivatives have also been illustrated as anti-TB 
agents, compound 22 (fig 7), which presents inhibitory activity with an 
IC50 value of 0.38 μM, its possible mechanism of action is through 
glutamine synthetase inhibition. This would be the first inhibitor 
compound not derived from amino acids [33]. Another series of pyridine 
derivatives were developed, compound 23, a potent anti-TB agent with 
activity similar to RIF. The results showed that an imidazole group as a 
substituent is equivalent to a nitro phenyl group, which has been 





Figure 7: Pyridine derivatives with potential activity anti-TB 
(24,25). 
Another important heterocyclic for the design of anti-TB 
compounds is a pyridazine moiety. In these compounds a relationship 
between Br, Cl and CH3 substituents, respectively, with Br and vinyl has 
been found with a favorable anti-TB activity. In these compounds there is 
an influence of the substituents X in para-position on the aromatic ring, 
where the activity is increased in the following order: CH3<Cl< Br with 
the activity being affected by the R1 substituents, where the most active 
compounds have a CH3 group (26, fig 8) [35]. 
 
26 
Figure 8: N-substituted-pyridazinones derivatives (26). 
The thiosemicarbazone derivatives can be used in TB therapy 
and prophylaxis. The 1H-2-thiosemicarbazoneindolinone derivatives 
indicated that halogenation of R1, elongation of the alkyl chain in R2, 
substitutions of the alkyl chain in R2 with cyclohexyl or phenyl, and the 
presence of a substituent in R3, are more efficient for increasing anti-TB 
activity, while R1 substitutions with a nitro group produce the most 
active compounds. The presence of a morpholine ring in Schiff bases 
substituted in R1 with a nitro group has a significant impact on anti-TB 
activity. The results indicated that the elongation of the alkyl chain 
increases activity. This enhanced activity is related to lipophilicity 
properties. Also, replacement of the alkyl chain in R2 and phenyl 
unsubstituted ciclohexyl has led to more active compounds (27). The 
absence of substitutions at N1 on the indole ring and increased 
lipophilicity appear to be responsible for high activity against M. 
tuberculosis [36]. The thiosemicarbazone-derived compounds have 
exhibited important anti-TB activity with an IC50 value of 2.59 uM/ml, is 
compound 28 (fig9) [37]. 
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Figure 9: Structure of 1H-indole-2,3-dione 3-thiosemicarbazone 
with anti-TB activity (27,28). 
Other moieties used in the design of anti-TB drugs are 
phenazine and benzothidiazine particularly benzothidiazine 1,1-dioxide 
constituents are an important anti-TB agents (29, fig 10). These 
compounds are indicates that the furan and thiophene group linked to 
benzothidiazine through a methylen bridge exhibited good anti-TB 
activity. The conjugated thiophene derivative showed moderate activity 
and is enhanced when it presents a nitrofuran group. The elimination of 
the methylene group with a carbonyl group leads to a loss of activity. The 
piperazine-benzothidiazine with methylene linkage (30, fig 10) is an 




Figure 10: Benzothiadiazine derivatives as anti-TB agents (29,30). 
 
5. Other non nitrogen heterocyclic derivatives 
The hybrid compound has been used for the design of anti-TB 
agents such as compound 31 (figure 11), formed from dibenzofuran and 
2,2- dimethylpyran subunits. The modifications of benzofurobenzopyran 
have showed less active compounds such as compound 32, where the 
furan B ring is replaced by an ether linker, a carbonyl group, a 
hydroxymethylene or a methylene group. The modifications such as 
acylation and bromination in 5-position on the C ring have produced 
inactive compounds. Other derivatives of compound 31, substitutions 
with a hydroxy, methoxy, or halogen group on benzofurobenzopyran 
increases anti-TB activity. The hydroxy compounds with good activity 
also showed cytotoxic activity on VERO cells. Halogenated compounds 
with a Cl or Br atom in 8, 9 and 11-position, exhibit improved potency 
than compound 31. The potency was significantly decreased when the A 
ring was substituted by an electron withdrawing group. The electron 
donating group substitutions such as hydroxy or methoxy showed 
significant increase activity (33). All these compounds showed a possible 
mechanism of action of interaction with lipid biosynthesis of the M. 







Figure 11: Structure of benzofurobenzopyrane as anti-TB agents 
(31-33). 
Other compounds with phthalimide moiety have described as 
biophoro to design new drugs with different biological activities. The 
hybridization of both phthalimide (thalidomide) and sulfonamide 
(dapsone) moiety leads to compounds with antileprotic activity. The 
design of new compounds with anti-TB activity is interesting. A series of 
derivatives showed that if the pyrimidine ring is substituted in any 
position or changed by an isosteric, this decreases anti-TB activity. 
Amino group substitutions by phthalimide ring also lead to a decrease 
anti-TB activity (34, fig 12). Modifications in the pyridine ring decrease 
anti-TB activity. The phthalimide group by molecular hybridization did 
not produce compounds with activity similar to INH; however, it allowed 
for compounds with MIC values similar to PZA [40].  
 
34 
Figure 12: Phthalimide derivatives as anti-TB agent (34) 
The compounds that act as inhibitors of the FAS-II system, 
diphenyl ether that interact with enzyme-cofactor binary complex, new 
compounds such as indols, benzofuran and cinnamic acid derivatives 
have been reported. Development of cinnamic acid derivatives would 
focus on more specific FAS-II inhibitors. A series of compounds 35 (fig 
13) was determined that addition of an alkyl chain increases anti-TB 
activity. The compound 64was the most active substance with an MIC of 
0.1μg/ml[41]. The amide derivatives of fatty acids have anti-TB activity. 
These compounds are designed to penetrate bacterial cells, which can be 
useful for the mechanism of INH resistance, this can be due to factors 
such as mutations in unknown genes, decreased permeability, or 
increased efflux [42]. 
 
35 
Figure 13: Cinnamic derivatives (35). 
 
6. Drugs in clinical trials 
The bicyclic nitroimidazofurane derivatives have anti-TB 
activity, such as CGI-17341, this compound is mutagenic. This has led to 
the development of PA-824. Its mechanism of action is to inhibit M. 
tuberculosis cell wall lipids and protein synthesis. It also inhibits non-
replicating bacteria. The derived oxazoles as anti-TB compounds led to 
the development of OPC- 67683, which has excellent activity in sensitive 
and resistant M. tuberculosis strains. Its mechanism of action involves 
inhibition of the synthesis of keto-mycolic, and methoxy-mycolic acid, 
although is possible another possible mechanism of action or interaction 
with another drug target in M. tuberculosis. The OPC-67683 also acts as a 
prodrug, since M. tuberculosis metabolizes it and produces as a product 
desnitro-imidazooxazole metabolite. TMC207 is a quinoline derivative 
with potent anti-TB activity in susceptible, DR and XDR strains. Its 
mechanism of action involves inhibition of ATP synthase that binds the 
M. tuberculosis membrane and there is a synergistic effect between 
TMC207 and PZA. Other very promising compounds anti-TB compounds 
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7.  Conclusion 
Tuberculosis remains the leading infectious disease 
worldwide, despite the availability of TB chemotherapy and the BCG 
vaccine. Structure-based drug design strategies have allowed the 
discovery of new anti-TB drugs [46,47]. These are increasingly receiving 
more attention, and a large number of new compounds from existing 
drugs are under investigation. 
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